Shanshan Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shanshan Zeng has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Le Xie
Department of Neurology, Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine (The Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine), Changsha, China
6 shared publications - Dahua Wu
Department of Neurology, Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine (The Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine), Changsha, China
5 shared publications - Xiongxing Sun
Department of Neurology Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine (The Affiliated Hospital of Hunan Academy Traditional Chinese Medicine) Changsha 410006 Hunan China
5 shared publications - Xukun Tang
Graduate School of Hunan University of Chinese Medicine, Changsha, CN
4 shared publications - Jie Tang
Graduate School of Hunan University of Chinese Medicine, Changsha, CN
2 shared publications - Lingying Wu
Graduate School, Hunan University of Traditional Chinese Medicine, Changsha, China
2 shared publications
Latest Publications
- Open Access
- 10 March 2026
- Published by Elsevier in SSRN Electronic Journal
Baishao Luoshi Formula Enhances Motor Recovery and Axonal Regeneration in Post-Stroke Spasticity Rats via the cAMP/PKA/p-CREB Pathway
Axonal regeneration plays a crucial role in the restoration of neural connectivity and motor function following cerebral infarction. This study sought to investigate the potential of the Baishao Luoshi Formula (BSLSF) to enhance long-term motor function in model rats by promoting axonal regeneration through the cyclic adenosine monophosphate (cAMP)/protein Kinase A (PKA)/phosphorylated cAMP response element-binding protein (p-CREB) signaling pathway. The right MCAO model was induced using suture occlusion. Fourteen days following model induction, biotinylated dextran amine (BDA) was administered into the left motor cortex for anterograde axonal tracing. Treatment commenced three days post-surgery and continued for 28 days. Motor function and spasticity were evaluated using rotarod tests and H-reflex measurements. Neuronal damage was assessed through histopathological (H&E staining, Nissl staining) and ultrastructural (Transmission Electron Microscope) analyses. Additionally, immunofluorescence, Western blotting, Real-time quantitative fluorescence PCR, and immunohistochemistry were utilized to detect axonal markers, synaptic proteins, and the activity of the cAMP/PKA/p-CREB pathway. The results demonstrated that BSLSF significantly enhanced motor coordination and muscle endurance while reducing spasticity in MCAO rats. Pathological and transmission electron microscopy analyses indicated a decrease in neuronal death and tissue damage. BSLSF was found to upregulate the expression of β-III tubulin, choline acetyltransferase (ChAT), growth associated protein-43 (GAP43), and p-CREB in the motor cortex, facilitate BDA-positive axonal regeneration in the corticospinal tract, and activate the cAMP/PKA/CREB signaling pathway. In conclusion, BSLSF mitigates PSS by promoting axonal regeneration through the activation of the cAMP/PKA/p-CREB pathway, presenting a potential therapeutic strategy for enhancing motor recovery following a stroke.
- 10 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBaishao Luoshi Formula Enhances Motor Recovery and Axonal Regeneration in Post-Stroke Spasticity Rats via the cAMP/PKA/p-CREB Pathway
Axonal regeneration plays a crucial role in the restoration of neural connectivity and motor function following cerebral infarction. This study sought to investigate the potential of the Baishao Luoshi Formula (BSLSF) to enhance long-term motor function in model rats by promoting axonal regeneration through the cyclic adenosine monophosphate (cAMP)/protein Kinase A (PKA)/phosphorylated cAMP response element-binding protein (p-CREB) signaling pathway. The right MCAO model was induced using suture occlusion. Fourteen days following model induction, biotinylated dextran amine (BDA) was administered into the left motor cortex for anterograde axonal tracing. Treatment commenced three days post-surgery and continued for 28 days. Motor function and spasticity were evaluated using rotarod tests and H-reflex measurements. Neuronal damage was assessed through histopathological (H&E staining, Nissl staining) and ultrastructural (Transmission Electron Microscope) analyses. Additionally, immunofluorescence, Western blotting, Real-time quantitative fluorescence PCR, and immunohistochemistry were utilized to detect axonal markers, synaptic proteins, and the activity of the cAMP/PKA/p-CREB pathway. The results demonstrated that BSLSF significantly enhanced motor coordination and muscle endurance while reducing spasticity in MCAO rats. Pathological and transmission electron microscopy analyses indicated a decrease in neuronal death and tissue damage. BSLSF was found to upregulate the expression of β-III tubulin, choline acetyltransferase (ChAT), growth associated protein-43 (GAP43), and p-CREB in the motor cortex, facilitate BDA-positive axonal regeneration in the corticospinal tract, and activate the cAMP/PKA/CREB signaling pathway. In conclusion, BSLSF mitigates PSS by promoting axonal regeneration through the activation of the cAMP/PKA/p-CREB pathway, presenting a potential therapeutic strategy for enhancing motor recovery following a stroke.
- Open Access
- 1 January 2026
- Published by Wiley in Neural Plasticity
- Vol. 2026 (1) , 3095088
Spatiotemporal Remodeling of Neural Excitability Following Ischemic Stroke: Regional Mechanisms From the Infarct Core to Brainstem–Spinal Output Systems: A Structured Narrative Review
Changes in neural excitability after ischemic stroke affect lesion growth, recovery of function, and long‐term motor problems. People often think of these changes as just an increase or decrease in neural activity. This view does not explain why excitability changes are different at different stages, brain regions, or mechanisms. It also does not explain why these changes can cause injury, help recovery, or lead to maladaptation. In the acute phase, the main areas involved are the infarct core and the ischemic penumbra. Here, excitability problems include membrane instability, prolonged depolarization, spreading depolarizations (SDs), changes in the fluid environment, and abnormal neurovascular responses. These problems together create harmful excitability that makes the lesion bigger. In the subacute phase, the dominant substrates shift toward the peri‐infarct cortex, ipsilesional primary motor cortex, and bilateral sensorimotor networks. Here, excitability changes are defined by excitatory–inhibitory rebalancing, reduction of excessive tonic inhibition, restoration of cortical responsiveness, and experience‐dependent network reorganization, forming restorative excitability that supports neural plasticity and functional recovery. During the subacute phase, excitatory–inhibitory rebalancing becomes a key synaptic mechanism of recovery, involving glutamatergic transmission, γ‐aminobutyric acid (GABA)ergic tonic and phasic inhibition, synaptic scaling, dendritic remodeling, and activity‐dependent refinement of surviving peri‐infarct circuits. In the chronic phase, in a subset of patients, the dominant substrates further shift toward the brainstem‐spinal output system, where compensatory recruitment of alternative descending pathways may contribute to abnormal synergies, spasticity, and low‐resolution motor control, representing maladaptive hyperexcitability. We therefore argue that poststroke excitability should not be interpreted within a static high‐/low‐excitability dichotomy but defined by when it occurs, where it is expressed, and at which mechanistic level it predominates.
- 1 January 2026
- Published by Wiley in Neural Plasticity
- Vol. 2026 (1) , 3095088
Open AccessSpatiotemporal Remodeling of Neural Excitability Following Ischemic Stroke: Regional Mechanisms From the Infarct Core to Brainstem–Spinal Output Systems: A Structured Narrative Review
Changes in neural excitability after ischemic stroke affect lesion growth, recovery of function, and long‐term motor problems. People often think of these changes as just an increase or decrease in neural activity. This view does not explain why excitability changes are different at different stages, brain regions, or mechanisms. It also does not explain why these changes can cause injury, help recovery, or lead to maladaptation. In the acute phase, the main areas involved are the infarct core and the ischemic penumbra. Here, excitability problems include membrane instability, prolonged depolarization, spreading depolarizations (SDs), changes in the fluid environment, and abnormal neurovascular responses. These problems together create harmful excitability that makes the lesion bigger. In the subacute phase, the dominant substrates shift toward the peri‐infarct cortex, ipsilesional primary motor cortex, and bilateral sensorimotor networks. Here, excitability changes are defined by excitatory–inhibitory rebalancing, reduction of excessive tonic inhibition, restoration of cortical responsiveness, and experience‐dependent network reorganization, forming restorative excitability that supports neural plasticity and functional recovery. During the subacute phase, excitatory–inhibitory rebalancing becomes a key synaptic mechanism of recovery, involving glutamatergic transmission, γ‐aminobutyric acid (GABA)ergic tonic and phasic inhibition, synaptic scaling, dendritic remodeling, and activity‐dependent refinement of surviving peri‐infarct circuits. In the chronic phase, in a subset of patients, the dominant substrates further shift toward the brainstem‐spinal output system, where compensatory recruitment of alternative descending pathways may contribute to abnormal synergies, spasticity, and low‐resolution motor control, representing maladaptive hyperexcitability. We therefore argue that poststroke excitability should not be interpreted within a static high‐/low‐excitability dichotomy but defined by when it occurs, where it is expressed, and at which mechanistic level it predominates.
- Open Access
- 8 December 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e77661
Real-World Efficacy and Safety of Zishenyizhi Pill for Cognitive Impairment Associated With Cerebral Small Vessel Disease: Protocol for a Multicenter Prospective Observational Study
Background: Cerebral small vessel disease (CSVD) is a leading cause of vascular cognitive impairment, contributing to 36% to 67% of vascular dementia cases. Current therapies, primarily cholinesterase inhibitors, offer limited efficacy and significant adverse effects. Traditional Chinese medicine, particularly the zishenyizhi pill, which is a multiherb formulation targeting yin deficiency and blood stasis, has shown promise in preliminary studies but lacks robust clinical validation. Objective: We designed this study to evaluate the real-world efficacy and safety of zishenyizhi pill combined with conventional Western therapy for CSVD-related cognitive impairment. Methods: This multicenter, prospective, nonrandomized controlled trial enrolled 246 patients from 4 institutions in Hunan province, China. Participants were stratified into 2 groups: the intervention group received zishenyizhi pill plus standard Western therapy, whereas the control group received conventional integrated Chinese-Western therapy. Cognitive outcomes (Montreal Cognitive Assessment, Mini-Mental State Examination, Vascular Dementia Assessment Scale cognitive subscale, and Trail Making Test parts A and B), traditional Chinese medicine syndrome scores, and safety parameters were assessed over 12 weeks. Results: Participant recruitment is scheduled to commence in April 2025, with an anticipated enrollment of 246 participants by December 2026. At present, patient recruitment is underway, and preliminary analysis of medical record data is being conducted. Final data collection is expected to conclude by April 2027, with results projected for publication in September 2027. Conclusions: The anticipated findings suggest that zishenyizhi pill may improve multiple cognitive domains in patients with cognitive impairment associated with CSVD while demonstrating a favorable safety profile. If validated, zishenyizhi pill could serve as a safe and effective adjunctive therapy for CSVD-related cognitive dysfunction. Trial Registration: International Traditional Medicine Clinical Trial Registry ITMCTR2025000553; https://itmctr.ccebtcm.org.cn/mgt/project/view/-4790836881284495026 International Registered Report Identifier (IRRID): DERR1-10.2196/77661
- 8 December 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e77661
Open AccessReal-World Efficacy and Safety of Zishenyizhi Pill for Cognitive Impairment Associated With Cerebral Small Vessel Disease: Protocol for a Multicenter Prospective Observational Study
Background: Cerebral small vessel disease (CSVD) is a leading cause of vascular cognitive impairment, contributing to 36% to 67% of vascular dementia cases. Current therapies, primarily cholinesterase inhibitors, offer limited efficacy and significant adverse effects. Traditional Chinese medicine, particularly the zishenyizhi pill, which is a multiherb formulation targeting yin deficiency and blood stasis, has shown promise in preliminary studies but lacks robust clinical validation. Objective: We designed this study to evaluate the real-world efficacy and safety of zishenyizhi pill combined with conventional Western therapy for CSVD-related cognitive impairment. Methods: This multicenter, prospective, nonrandomized controlled trial enrolled 246 patients from 4 institutions in Hunan province, China. Participants were stratified into 2 groups: the intervention group received zishenyizhi pill plus standard Western therapy, whereas the control group received conventional integrated Chinese-Western therapy. Cognitive outcomes (Montreal Cognitive Assessment, Mini-Mental State Examination, Vascular Dementia Assessment Scale cognitive subscale, and Trail Making Test parts A and B), traditional Chinese medicine syndrome scores, and safety parameters were assessed over 12 weeks. Results: Participant recruitment is scheduled to commence in April 2025, with an anticipated enrollment of 246 participants by December 2026. At present, patient recruitment is underway, and preliminary analysis of medical record data is being conducted. Final data collection is expected to conclude by April 2027, with results projected for publication in September 2027. Conclusions: The anticipated findings suggest that zishenyizhi pill may improve multiple cognitive domains in patients with cognitive impairment associated with CSVD while demonstrating a favorable safety profile. If validated, zishenyizhi pill could serve as a safe and effective adjunctive therapy for CSVD-related cognitive dysfunction. Trial Registration: International Traditional Medicine Clinical Trial Registry ITMCTR2025000553; https://itmctr.ccebtcm.org.cn/mgt/project/view/-4790836881284495026 International Registered Report Identifier (IRRID): DERR1-10.2196/77661
- Open Access
- 17 May 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Real-World Efficacy and Safety of Zishenyizhi Pill for Cognitive Impairment Associated With Cerebral Small Vessel Disease: Protocol for a Multicenter Prospective Observational Study (Preprint)
BACKGROUND Cerebral small vessel disease (CSVD) is a leading cause of vascular cognitive impairment, contributing to 36% to 67% of vascular dementia cases. Current therapies, primarily cholinesterase inhibitors, offer limited efficacy and significant adverse effects. Traditional Chinese medicine, particularly the zishenyizhi pill, which is a multiherb formulation targeting yin deficiency and blood stasis, has shown promise in preliminary studies but lacks robust clinical validation. OBJECTIVE We designed this study to evaluate the real-world efficacy and safety of zishenyizhi pill combined with conventional Western therapy for CSVD-related cognitive impairment. METHODS This multicenter, prospective, nonrandomized controlled trial enrolled 246 patients from 4 institutions in Hunan province, China. Participants were stratified into 2 groups: the intervention group received zishenyizhi pill plus standard Western therapy, whereas the control group received conventional integrated Chinese-Western therapy. Cognitive outcomes (Montreal Cognitive Assessment, Mini-Mental State Examination, Vascular Dementia Assessment Scale cognitive subscale, and Trail Making Test parts A and B), traditional Chinese medicine syndrome scores, and safety parameters were assessed over 12 weeks. RESULTS Participant recruitment is scheduled to commence in April 2025, with an anticipated enrollment of 246 participants by December 2026. At present, patient recruitment is underway, and preliminary analysis of medical record data is being conducted. Final data collection is expected to conclude by April 2027, with results projected for publication in September 2027. CONCLUSIONS The anticipated findings suggest that zishenyizhi pill may improve multiple cognitive domains in patients with cognitive impairment associated with CSVD while demonstrating a favorable safety profile. If validated, zishenyizhi pill could serve as a safe and effective adjunctive therapy for CSVD-related cognitive dysfunction. CLINICALTRIAL International Traditional Medicine Clinical Trial Registry ITMCTR2025000553; https://itmctr.ccebtcm.org.cn/mgt/project/view/-4790836881284495026 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/77661
- 17 May 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessReal-World Efficacy and Safety of Zishenyizhi Pill for Cognitive Impairment Associated With Cerebral Small Vessel Disease: Protocol for a Multicenter Prospective Observational Study (Preprint)
BACKGROUND Cerebral small vessel disease (CSVD) is a leading cause of vascular cognitive impairment, contributing to 36% to 67% of vascular dementia cases. Current therapies, primarily cholinesterase inhibitors, offer limited efficacy and significant adverse effects. Traditional Chinese medicine, particularly the zishenyizhi pill, which is a multiherb formulation targeting yin deficiency and blood stasis, has shown promise in preliminary studies but lacks robust clinical validation. OBJECTIVE We designed this study to evaluate the real-world efficacy and safety of zishenyizhi pill combined with conventional Western therapy for CSVD-related cognitive impairment. METHODS This multicenter, prospective, nonrandomized controlled trial enrolled 246 patients from 4 institutions in Hunan province, China. Participants were stratified into 2 groups: the intervention group received zishenyizhi pill plus standard Western therapy, whereas the control group received conventional integrated Chinese-Western therapy. Cognitive outcomes (Montreal Cognitive Assessment, Mini-Mental State Examination, Vascular Dementia Assessment Scale cognitive subscale, and Trail Making Test parts A and B), traditional Chinese medicine syndrome scores, and safety parameters were assessed over 12 weeks. RESULTS Participant recruitment is scheduled to commence in April 2025, with an anticipated enrollment of 246 participants by December 2026. At present, patient recruitment is underway, and preliminary analysis of medical record data is being conducted. Final data collection is expected to conclude by April 2027, with results projected for publication in September 2027. CONCLUSIONS The anticipated findings suggest that zishenyizhi pill may improve multiple cognitive domains in patients with cognitive impairment associated with CSVD while demonstrating a favorable safety profile. If validated, zishenyizhi pill could serve as a safe and effective adjunctive therapy for CSVD-related cognitive dysfunction. CLINICALTRIAL International Traditional Medicine Clinical Trial Registry ITMCTR2025000553; https://itmctr.ccebtcm.org.cn/mgt/project/view/-4790836881284495026 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/77661
- Open Access
- 27 August 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e65829
Exploring the time to onset and early predictors of Post-stroke spasticity combined with surface electromyography (sEMG): study protocol for a nested case-control (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Post-stroke spasticity (PSS) is a frequent sequela in patients who have suffered a stroke. This form of paralysis is more prevalent compared to other post-stroke sequelae and is among the most challenging and complex symptoms to manage. Surface electromyography (sEMG) can reflect the physiological information of muscles in real time and is highly beneficial in diagnosing neuromuscular diseases in clinical medicine. This study aimed to investigate the timing of post-stroke limb spasms using a nested case-control study combined with sEMG and to identify and predict factors of PSS at an early stage. Objective: This clinical study aimed to improve the prognosis of patients with PSS by exploring the time of PSS occurrence through a nested case-control study, early identification, and prediction of PSS factors. Methods: This was a nested case-control study. Participants were assessed within 24 h of the onset of hospitalization using a standardized case report form to evaluate general patient information and clinical data related to cerebral infarction and imaging. Upon inclusion, patients were assessed after 1, 2, 4, 8, and 12 weeks, using the Modified Ashworth Scale (MAS) for spasticity severity, root mean square (RMS) values from (sEMG) for limb spasm severity, and the simplified Fugl-Meyer Assessment (S-FM) for limb motor function. Patients who experienced spasticity within 12 weeks were assigned to the spasticity group, whereas those who did not experience spasticity were assigned to the control group. Unmatched case grouping was implemented. Data with normal distribution was analyzed using the t-test, while data with non-normal distribution was analyzed using the rank-sum test; categorical data was analyzed using the chi-square test, rank-sum test, or Fisher's exact test. Logistic regression analysis was used to investigate factors affecting treatment outcomes. Data processing, analysis, and visualization were conducted using Statistical Package for the Social Sciences software (version 26.0). Results: The patient is still being recruited Conclusions: The patient is still being recruited Clinical Trial: Ethics and dissemination: The study has been approved by the Ethics Committee of the Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine (approval number: [202371]). All patients were required to provide a written informed consent before enrollment. The findings of this investigation were mandated for publication in peer-reviewed journals. Clinical trial registration: ClinicalTrials.gov ChiCTR2300077121.
- 27 August 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14, e65829
Open AccessExploring the time to onset and early predictors of Post-stroke spasticity combined with surface electromyography (sEMG): study protocol for a nested case-control (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Post-stroke spasticity (PSS) is a frequent sequela in patients who have suffered a stroke. This form of paralysis is more prevalent compared to other post-stroke sequelae and is among the most challenging and complex symptoms to manage. Surface electromyography (sEMG) can reflect the physiological information of muscles in real time and is highly beneficial in diagnosing neuromuscular diseases in clinical medicine. This study aimed to investigate the timing of post-stroke limb spasms using a nested case-control study combined with sEMG and to identify and predict factors of PSS at an early stage. Objective: This clinical study aimed to improve the prognosis of patients with PSS by exploring the time of PSS occurrence through a nested case-control study, early identification, and prediction of PSS factors. Methods: This was a nested case-control study. Participants were assessed within 24 h of the onset of hospitalization using a standardized case report form to evaluate general patient information and clinical data related to cerebral infarction and imaging. Upon inclusion, patients were assessed after 1, 2, 4, 8, and 12 weeks, using the Modified Ashworth Scale (MAS) for spasticity severity, root mean square (RMS) values from (sEMG) for limb spasm severity, and the simplified Fugl-Meyer Assessment (S-FM) for limb motor function. Patients who experienced spasticity within 12 weeks were assigned to the spasticity group, whereas those who did not experience spasticity were assigned to the control group. Unmatched case grouping was implemented. Data with normal distribution was analyzed using the t-test, while data with non-normal distribution was analyzed using the rank-sum test; categorical data was analyzed using the chi-square test, rank-sum test, or Fisher's exact test. Logistic regression analysis was used to investigate factors affecting treatment outcomes. Data processing, analysis, and visualization were conducted using Statistical Package for the Social Sciences software (version 26.0). Results: The patient is still being recruited Conclusions: The patient is still being recruited Clinical Trial: Ethics and dissemination: The study has been approved by the Ethics Committee of the Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine (approval number: [202371]). All patients were required to provide a written informed consent before enrollment. The findings of this investigation were mandated for publication in peer-reviewed journals. Clinical trial registration: ClinicalTrials.gov ChiCTR2300077121.
- Open Access
- 27 August 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Exploring the Time to Onset and Early Predictors of Poststroke Spasticity Combined With Surface Electromyography: Protocol for a Nested Case-Control Study (Preprint)
BACKGROUND Poststroke spasticity (PSS) is a frequent sequela in patients who have experienced stroke. This form of paralysis is more prevalent compared to other poststroke sequelae and is among the most challenging and complex symptoms to manage. Surface electromyography (sEMG) can reflect the physiological information of muscles in real time and is highly beneficial in diagnosing neuromuscular diseases in clinical medicine. OBJECTIVE This study aimed to investigate the timing of poststroke limb spasms using a nested case-control study combined with sEMG and to identify and predict factors of PSS at an early stage. METHODS This was a nested case-control study. Participants were assessed within 24 hours of the onset of hospitalization using a standardized case report form to evaluate general patient information and clinical data related to cerebral infarction and imaging. Upon inclusion, patients were assessed after 1, 2, 4, 8, and 12 weeks, using the Modified Ashworth Scale (MAS) for spasticity severity, root mean square values from sEMG for limb spasm severity, and the simplified Fugl-Meyer (S-FM) Assessment for limb motor function. Patients who experienced spasticity within 12 weeks were assigned to the spasticity group, whereas those who did not experience spasticity were assigned to the control group. Unmatched case grouping was implemented. Data with normal distribution were analyzed using the t test, while data with nonnormal distribution were analyzed using the rank-sum test; categorical data were analyzed using the chi-square test, rank-sum test, or Fisher exact test. Logistic regression analysis was used to investigate factors affecting treatment outcomes. Data processing, analysis, and visualization were conducted using Statistical Package for the Social Sciences software (version 26.0; IBM Corp). RESULTS This study is funded by the Chinese Association of Ethnic Medicine and began participant recruitment and registration in November 2023. The study is currently ongoing, with 66 participants enrolled as of March 2025. CONCLUSIONS This study selected a diagnostic method combining sEMG and subjective scales to determine PSS, aiming to eliminate diagnostic errors caused by subjective assessments. This study adopted a nested case-control study method, which has minimal information bias, allowing for the inference of causal relationships between exposure and disease. CLINICALTRIAL Chinese Clinical Trial Registry ChiCTR2300077121; https://www.chictr.org.cn/showproj.html?proj=205037 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/65829
- 27 August 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessExploring the Time to Onset and Early Predictors of Poststroke Spasticity Combined With Surface Electromyography: Protocol for a Nested Case-Control Study (Preprint)
BACKGROUND Poststroke spasticity (PSS) is a frequent sequela in patients who have experienced stroke. This form of paralysis is more prevalent compared to other poststroke sequelae and is among the most challenging and complex symptoms to manage. Surface electromyography (sEMG) can reflect the physiological information of muscles in real time and is highly beneficial in diagnosing neuromuscular diseases in clinical medicine. OBJECTIVE This study aimed to investigate the timing of poststroke limb spasms using a nested case-control study combined with sEMG and to identify and predict factors of PSS at an early stage. METHODS This was a nested case-control study. Participants were assessed within 24 hours of the onset of hospitalization using a standardized case report form to evaluate general patient information and clinical data related to cerebral infarction and imaging. Upon inclusion, patients were assessed after 1, 2, 4, 8, and 12 weeks, using the Modified Ashworth Scale (MAS) for spasticity severity, root mean square values from sEMG for limb spasm severity, and the simplified Fugl-Meyer (S-FM) Assessment for limb motor function. Patients who experienced spasticity within 12 weeks were assigned to the spasticity group, whereas those who did not experience spasticity were assigned to the control group. Unmatched case grouping was implemented. Data with normal distribution were analyzed using the t test, while data with nonnormal distribution were analyzed using the rank-sum test; categorical data were analyzed using the chi-square test, rank-sum test, or Fisher exact test. Logistic regression analysis was used to investigate factors affecting treatment outcomes. Data processing, analysis, and visualization were conducted using Statistical Package for the Social Sciences software (version 26.0; IBM Corp). RESULTS This study is funded by the Chinese Association of Ethnic Medicine and began participant recruitment and registration in November 2023. The study is currently ongoing, with 66 participants enrolled as of March 2025. CONCLUSIONS This study selected a diagnostic method combining sEMG and subjective scales to determine PSS, aiming to eliminate diagnostic errors caused by subjective assessments. This study adopted a nested case-control study method, which has minimal information bias, allowing for the inference of causal relationships between exposure and disease. CLINICALTRIAL Chinese Clinical Trial Registry ChiCTR2300077121; https://www.chictr.org.cn/showproj.html?proj=205037 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/65829